
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is positioned for a multiyear structural growth opportunity because PROGRESS, together with real-world evidence from Généreux and Kardigan, suggests moderate AS is both common and clinically meaningful rather than a narrow edge case. The registry found 78.7% of 35,343 moderate AS patients had at least one at-risk feature, while about 45,000-patient Kardigan data showed roughly 27% progressed rapidly, reinforcing that earlier intervention could expand TAVR demand beyond severe disease alone. That thesis is supported by execution: Q3 revenue rose 11.2% ex-FX to $1.72B, TAVR sales increased 8.8% to $1.24B, and FY26 guidance was raised to about 11.5% growth with adj. EPS of $2.97-$3.05.
Bears say
Edwards Lifesciences is facing a negative outlook because its growth depends on continued expansion in TAVR and TMTT, yet the company itself flags lower-than-anticipated TAVR penetration, weaker-than-expected adoption of the TMTT portfolio, and setbacks in TMVR development that could limit commercialization. It also faces competitive pressure globally from newer entrants and existing rivals, plus regulatory delays, clinical trial failures, and intellectual property challenges that could erode share and delay product launches. On top of that, macro and operating headwinds such as staffing shortages, supply chain or manufacturing disruptions, FX volatility, pricing pressure, and economic or political uncertainty in developed and emerging markets threaten margins and the roughly 60% of sales generated outside the US.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Edwards Lifesciences (EW) Forecast
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares